Furthermore, the TLR4/MyD88/MAPK signaling pathway was observed to be involved in the mechanism of the protective effect of dexmedetomidine on the lung following I/R injury, although an α2-adrenergic antagonist failed to neutralize the effect of dexmedetomidine on acute ischemia-induced lung injury. Here, MYD88 is linked to ischemia.